Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study

ConclusionsTo our knowledge, this is the first population-based study of olaparib real-world use and outcomes. During the first three years following regulatory approval, olaparib was mainly prescribed to ovarian cancer patients. Ovarian cancer patients stayed on olaparib for a median of 9.5  months and the treatment appeared to be well tolerated.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research